A 38-year-old woman with acanthosis nigricans presents with symmetric, velvety, hyperpigmented plaques in the axillae, posterior neck, and inframammary folds. Laboratory evaluation reveals fasting glucose 126 mg/dL, HbA1c 7.2%, and elevated fasting insulin consistent with hyperinsulinemia. BMI is 32 kg/m². The structure marked **A** in the diagram represents the most appropriate management approach for this patient's underlying pathophysiology. Which of the following best describes the rationale for the intervention marked **A**?
A. Laser ablation of affected skin areas provides definitive cure by destroying the hyperkeratotic papillomatosis without need for systemic intervention
B. Topical antifungals eliminate secondary fungal colonization and prevent progression of the velvety plaques
C. Weight reduction and metformin address hyperinsulinemia and insulin resistance, the primary drivers of keratinocyte and fibroblast proliferation in obesity-associated acanthosis nigricans
D. Reassurance and observation are sufficient, as acanthosis nigricans in this setting is purely cosmetic and carries no metabolic risk
Explanation
Why option 1 is correct
The clinical anchor is that obesity-associated acanthosis nigricans (the most common form) is driven by HYPERINSULINEMIA acting at supraphysiologic concentrations on IGF-1 receptors on keratinocytes and fibroblasts, leading to excessive proliferation and the characteristic velvety, hyperpigmented, hyperkeratotic plaques. Weight reduction and metformin directly address this pathophysiology: weight loss reduces insulin resistance and hyperinsulinemia, while metformin improves insulin sensitivity. This is the evidence-based first-line management for obesity-associated AN and is reversible with intervention. The patient's elevated fasting insulin and HbA1c confirm the metabolic basis. Per Bolognia Dermatology 4th ed and AAD guidelines, management centers on the underlying cause — in this case, insulin resistance and metabolic syndrome.
Why each distractor is wrong
Option 2 (Topical antifungals): Acanthosis nigricans is NOT a fungal infection. The dark appearance results from acanthotic papillomatosis and hyperkeratosis, not fungal colonization. While secondary fungal infection may occur in intertriginous areas, antifungals do not address the underlying growth-factor-driven proliferation and are not first-line therapy.
Option 3 (Laser ablation only): Laser ablation treats only the cutaneous manifestation without addressing the underlying hyperinsulinemia and insulin resistance. It does not prevent recurrence or progression and ignores the systemic metabolic disease. Bolognia explicitly states that treatment must target the underlying cause; ablation alone is insufficient and cosmetically temporary.
Option 4 (Reassurance only): This approach dangerously minimizes the clinical significance of acanthosis nigricans. The presence of AN in this patient indicates metabolic syndrome, type 2 diabetes, and increased cardiovascular risk. Failure to intervene leaves the patient's insulin resistance, hyperglycemia, and dyslipidemia untreated, perpetuating systemic disease and skin manifestations.
High-YieldNEET PG
Acanthosis nigricans is a cutaneous window into systemic insulin resistance; management must target the underlying metabolic derangement (weight loss, metformin) rather than the skin alone.
